Biomedicines, Год журнала: 2024, Номер 12(11), С. 2469 - 2469

Опубликована: Окт. 28, 2024

In this review, we seek to explore two distinct approaches the clinical management of OA: a prospective approach, addressing primarily one’s genetic predisposition OA and generating early intervention options, retrospective aimed at halting or reversing progression post-symptom onset. The remains challenging, largely due limited availability preventative treatments failure existing therapies modify reverse underlying pathophysiology. approach involves identification markers associated with utilizes in vitro vivo models characterize disease mechanism. Further, focuses on identifying predispositions unique molecular subtypes develop individualized treatment plans based patient genotypes. While current literature investigating strategy has been notable, faces substantial challenges, such as extensive time burdens utilization testing that may not be economically feasible. Additionally, there is questionable justification for investigations, given OA’s relatively low mortality rates burden when contrasted diseases like specific forms cancer, which rely heavily approach. Alternatively, following symptom onset aims utilize novel therapeutics slow inflammatory cascade typically seen progression. These treatments, Hippo pathway inhibitors, have shown initial promise alleviating symptomology by modulating cellular processes preserve articular cartilage. comparison likely more cost-effective, widely applicable, does necessitate thorough invasive screening. However, must still weighed against typical natural history progression, frequently results total knee arthroplasty unacceptable outcomes 15–20% patients. From comparative analysis these approaches, review argues strategy, ideally lower economic greater accessibility, offers reasonable effective solution context management. Using similar other chronic diseases, suggest an “Inverted Pyramid” model algorithm, structured research development regimen prioritizes first, subsequent refinement resistance therapies. We argue reduce need while improving accessibility.

Язык: Английский